Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications, and (4) issues related to compounding and counterfeit drugs.
2025 · 2nd Quarter (Apr 1 - June 30)
NOVO NORDISK INC.
Filed by THE MADISON GROUP.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Termination
- Posted
- Jul 18, 2025
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- THE MADISON GROUP
- Client
- NOVO NORDISK INC.
- Filing UUID
- e69b3a5e-9f70-44e3-91de-86796facdb29
- Termination date
- May 31, 2025
Literal source text
Lobbying issues and bill citations
Issues and legislation related to (1) Medicare coverage of anti-obesity medications, (2) the 340B drug pricing program, and (3) Medicare Part D coverage of anti-obesity medications.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.